The impact of real-world cardiovascular-related pharmacogenetic testing in an insured population
| Autor: | Patrick Racsa, Jeffrey J. Ellis, Jennifer Billings, Charron Long, Kristine Bordenave |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Prescription drug Population Pharmacogenomic Testing 030204 cardiovascular system & hematology Medicare Advantage 03 medical and health sciences 0302 clinical medicine Health care Humans Medicine 030212 general & internal medicine education Aged Retrospective Studies education.field_of_study Insurance Health business.industry Retrospective cohort study Health Care Costs General Medicine Health Services Middle Aged United States Hospitalization Cardiovascular Diseases Case-Control Studies Emergency medicine Female business Medicaid Pharmacogenetics |
| Zdroj: | International Journal of Clinical Practice. 72:e13088 |
| ISSN: | 1368-5031 |
| DOI: | 10.1111/ijcp.13088 |
| Popis: | BACKGROUND Pharmacogenomics is intended to help clinicians provide the right drug to the right patient at an appropriate dose. However, limited evidence of clinical utility has slowed uptake of pharmacogenomic testing (PGT). OBJECTIVE To evaluate the impact of real-world cardiovascular (CV)-related PGT on clinical outcomes, healthcare resource utilisation (HCRU) and cost in a large, heterogeneous population. METHODS Individuals with Medicare Advantage Prescription Drug, Medicaid, or commercial coverage between 1/1/2011 and 9/30/2015 and ≥1 atherosclerotic CV-related diagnosis were identified. Those with ≥1 claim for CV-related PGT were included in the test group (index date = 1st PGT claim) and matched 1:2 to controls without PGT. Individuals aged |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|